Fingolimod and cardiac risk: Latest findings and clinical implications

Therapeutic Advances in Drug Safety

Volumn 4, Issue 3, 2013, Pages 119-124

  Vargas, Wendy s ^a   Perumal, Jai s ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

bradycardia; cardiovascular risks; drug safety; fingolimod

Indexed keywords

FINGOLIMOD; PLACEBO;

ARTICLE; ATRIOVENTRICULAR BLOCK; BLOOD BRAIN BARRIER; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEART ARREST; HUMAN; MULTIPLE SCLEROSIS; NERVE BLOCK; PATIENT SELECTION; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; QT PROLONGATION; SIDE EFFECT; SINUS BRADYCARDIA;

EID: 84880422774     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098613481023     Document Type: Article

References (40)

1. Bartholomaus I. Kawakami N. Odoardi F. (2009) Effector T cells interactions with the meningeal vascular structures in nascent autoimmune CNS lesions. Nature 462: 94–98.
2. Brinkmann V. (2009) FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune system and the central nervous system. Br J Pharmacol 158: 1173–1182.
3. Brinkmann V. Baumruker T. (2006) Pulmonary and vascular pharmacology of sphingosine 1-phosphate. Curr Opin Pharmacol 6: 244–250.
4. Castro-Borrero W. Graves D. Frohman T. Flores A. Hardeman P. Logan D. (2012) Current and emerging therapies in multiple sclerosis: a systematic review. Ther Adv Neurol Disord 5: 205–220.
5. Chun J. Brinkmann V. (2011) A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med 12: 213–228.
6. Chun J. Hartung H. (2010) Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 33: 91–101.
7. Coelho R. Payne S. Bittman R. Spiegel S. Sato-Bigbee C. (2007) The immunomodulator FTY720 has direct cytoprotective effect in oligodendrocyte progenotors. J Pharmacol Exp Ther 323: 626–635.
8. Cohen J. Barkhof F. Comi G. Hartung H. Khatri B. Montalban X. (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362: 402–412.
9. Cohen J. Chun J. (2011) Mechanism of fingolimod–s efficacy and adverse effects in multiple sclerosis. Ann Neurol 69: 759–777.
10. Comi G. O–Connor P. Montalban X. Antel J. Radue E. Karlsson G. (2010) Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler 16: 197–207.
11. Cusak K. Stoffel R. (2010) SIP receptor agonist: assessment of selectivity and current clinical activity. Curr Opin Drug Discov Dev 13: 481–488.
12. DiMarco J. O–Connor P. Cohen J. Francis G. Collins W. Zhang-Auberson L. (2010) First-dose effect of fingolimod: pooled safety data from two phase 3 studies (TRANSFORMS and FREEDOMS) (P830). Mult Scler 16(Suppl. 10): S290.
13. Espinosa P. Berger J. (2011) Delayed fingolimod-associated asystole. Mult Scler 17: 1387–1389.
14. EMA (2012) Questions and answers on the review of Gilenya. European Medicine–s Agency. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002202/human_med_001433.jsp&mid=WC0b01ac058001d124 (accessed 13 February 2013).
15. Faber H. Fischer H. Weber F. (2012) Prolonged and symptomatic bradycardia following a single dose of fingolimod. Mult Scler 19: 126–128.
16. Forrest M. Sun S. Hajdu R. Bergsstrom D. Card G. Doherty J. (2004) Immune cell regulation and cardiovascular effects of sphingosine-1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther 309: 758–759.
17. Foster C. Howard L. Schweitzer A. Persohn E. Hiestand P. Balatoni B. (2007) Brain penetration of the oral immunomudulatory drug FTY720 and its phosphorylation in central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 323: 469–475.
18. Graler M. Goetzl E. (2004) The immunosuppressant FTY720 downregulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 18: 551–553.
19. Guo J. MacDonell K. Giles W. (1999) Effects of sphigosine-1-phosphate on pacemaker activity in rabbit sino-atrial node cells. Pflugers Arch 438: 642–648.
20. Hla T. Brinkmann V. (2011) Sphingosine-1-phosphate (S1P): Physiology and the effects of S1P receptor modulation. Neurology 76(8 Suppl. 3): S3–S8.
21. Im D. (2003) Linking Chinese medicine and G-protein-coupled receptors. Trends Pharmacol Sci 24: 2–4.
22. Jackson S. Baker D. Giovannoni G. (2009) Fingolimod enhances myelin basic protein expression and modulates cytokine production following an interferon –gamma mediated insult in the whole brain aggregate cell culture system. Neurology 72(Suppl. 3): A377–A378.
23. Kappos L. Antel J. Comi G. Montalban X. O–Connor P. Polman C. (2006) Oral Fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355: 1124–1140.
24. Kappos L. Radue E. O–Connor P. Polman C. Hohlfeld R. Calabresi P. (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362: 387–401.
25. Lee M. Van Brocklyn J. Thangada S. Liu C. Hand A. Menzeleev R. (1998) Sphingosine-1-phosphate as a ligand for the G-protein coupled receptor EGD-1. Science 279: 1552–1555.
26. Lindsey J. Haden-Pinneri K. Momn N. Bija L. (2012) Sudden unexpected death on fingolimod. Mult Scler 10: 1–2.
27. Mandala S. Hajdu R. Bergstrom J. Quackenbush E. Xie J. Milligan J. (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate agonists. Science 296: 346–349.
28. Matloubian M. Lo C. Cinamon G. Lesneski M. Xu Y. Brinkman V. (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependant on SIP receptor 1. Nature 427: 355–360.
29. Mazurais D. Robert P. Gout B. Berrebi-Bertrand I. Laville M. Calmels T. (2002) Cell type-specific localization of human cardiac SIP receptors. J Histochem Cytochem 50: 661–670.
30. O–Connor P. Comi G. Montalban X. Antel J. Radue E. de Vera A. (2009) Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 72: 73–79.
31. Ortaneda D. Cohen J. (2011) Potential mechanisms of efficacy and adverse effects in the use of fingolimod (FTY720). Expert Rev Clin Pharmacol 4: 567–570.
32. Perumal J. Khan O. (2012) Emerging disease-modifying therapies in multiple sclerosis. Curr Treat Options Neurol 14: 256–263.
33. Peters S. Alewijnse A. (2007) Sphingosine-1-phosphate signaling in the cardiovascular system. Curr Opin Pharmacol 7: 186–192.
34. Rivera J. Proia R. Olivera A. (2008) The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol 8: 753–763.
35. Schmouder R. Serra D. Wang Y. Kovarik J. DiMarco J. Hunt T. (2006) FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. J Clin Pharmacol 46: 895–904.
36. Schwab S. Cyster J. (2007) Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol 8: 1295–1301.
37. Smiler B. (2004) Risperidol and asystole. Anesth Analg 99: 623.
38. Spiegel S. Milstien S. (2003) Sphingosine-1-phosphate: an enigmatic signaling lipid. Nat Rev Mol Cell Biol 4: 397–407.
39. Vosoughi R. Freedman M. (2010) Therapy of MS. Clin Neurol Neurosurg 112: 365–385.
40. Waeber C. Blondeau N. Salomone S. (2004) Vascular sphingosine-1-phosphate SIP1 and SIP3 receptors. Drug News Perspect 17: 731–739.